|
This document is a pathology peer review report by Experimental Pathology Laboratories, Inc. concerning mammary glands from a chronic feeding study in rats exposed to PFOA, sponsored by DuPont, which includes consensus diagnoses and statistical analyses of mammary tumors.
|
2005 |
AR226-3630
|
MMq1R2JRerKB24K7dXkOaKaN7 |
74 |
|
The document is a submission from 3M's Medical Department to the U.S. EPA regarding a Pathology Working Group report that concludes chronic dietary administration of PFOA did not affect the incidence of mammary gland neoplasms in female rats, based on a review of a chronic study conducted by 3M.
|
2005 |
AR226-3630
|
oeX1g9roGgVdvGerRRaaOeJX |
76 |
|
3M submitted comments to the EPA Science Advisory Board PFOA Review Panel regarding the risk assessment of perfluorooctanoic acid (PFOA), including points of departure and findings from related studies.
|
2005 |
AR226-3630
|
qapo2xyRXb77r1zEZ4K3dJxNq |
1 |
|
The document contains additional comments from 3M Company regarding the EPA Science Advisory Board's review of PFOA, along with a final report on the effects of perfluorobutanesulfonate, perfluorohexanesulfonate, and perfluorooctanesulfonate on cholesterol metabolism in vitro.
|
2005 |
AR226-3630
|
2RzoD2DrxjB28jraX36xjYNz6 |
1 |
|
The document is an analytical report from 3M Environmental Laboratory detailing the initial quantitative screening of commercial lots of human serum obtained in 2004 for endogenous fluorochemicals, including PFOA and PFOS, using protein precipitation and liquid chromatography/tandem mass spectrometry.
|
2005 |
AR226-3630
|
KRYQZpq4X7q2BZoy7Kd6kG4oo |
1 |
|
This document contains comments from various authors, including representatives from 3M and Hollyhouse, directed to the EPA Science Advisory Board PFOA Review Panel, dated February 2005.
|
2005 |
AR226-3630
|
oeOarqd48k2MLd093Xj30gZKX |
1 |
|
The document includes a series of communications from 3M regarding a pathology review of mammary glands from a chronic feeding study in rats with PFOA, highlighting findings related to mammary tumors.
|
2005 |
AR226-3630
|
Em0wKQGkegJLNpj65B3wvo6Lx |
1 |
|
The document is a final report on a 5-day inhalation toxicity study of Perfluorooctanesulfonyl Fluoride (POSF) conducted by Huntingdon Life Sciences Ltd. for 3M, detailing preliminary toxicity findings in CD rats.
|
2005 |
AR226-3630
|
p7DMez4jJn9gxov3M8M8Dn2E |
1 |
|
The document contains final reports from Huntingdon Life Sciences Ltd. on a 90-day inhalation toxicity study of Perfluorooctanesulfonyl Fluoride (POSF) administered to CD rats, detailing the study's methodology and findings.
|
2005 |
AR226-3630
|
Ozpnaz7N6xGb884KGwrjJakbp |
1 |
|
Empty document.
|
2005 |
AR226-3630
|
ZgYxLaorw4QBVY2KnZn5DaEJ |
1 |
|
The document is a letter from Hollvhouse Inc. to the EPA Science Advisory Board, providing comments on the scientific soundness of the "Draft Risk Assessment of the Potential Human Health Effects Associated with Exposure to Perfluorooctanoic Acid (PFOA) and Its Salts," specifically urging reconsideration of the selected endpoints for prenatal exposure assessment.
|
2005 |
AR226-3630
|
mqjRZr3mr2gdG9jx5eME1QDYO |
6 |
|
3M Company submitted comments to the EPA Science Advisory Board regarding the adequacy of human biomonitoring data for perfluorooctanoic acid (PFOA), asserting that the data, while not fully representative, provide a reasonable estimate of serum concentrations in the general population and support the near steady state assumption for calculating margins-of-exposure in the EPA's draft risk assessment.
|
2005 |
AR226-3630
|
DDVK2qJpJvXb5GJ9o4GgDzBQM |
10 |
|
The document is a letter from a consultant to the EPA Science Advisory Board providing comments on the draft risk assessment for PFOA, emphasizing the appropriateness of using the margin of exposure (MOE) approach for assessing potential health risks associated with PFOA exposure.
|
2005 |
AR226-3630
|
omD6X8y2nvyMpgoJLke6YJ82r |
4 |
|
The document is a submission from 3M to the U.S. EPA regarding a Pathology Working Group report that concludes chronic dietary administration of PFOA did not affect the incidence of mammary gland neoplasms in female rats, based on a review of a chronic study conducted by 3M.
|
2005 |
AR226-3630
|
06kqXOb1m2w6qqK36edXwvBvd |
2 |
|
3M Company submitted additional comments to the EPA Science Advisory Board regarding the risk assessment of perfluorooctanoic acid (PFOA), specifically addressing issues related to mammary tumors in rats and the interpretation of cancer data from their studies.
|
2005 |
AR226-3630
|
5DY7wR5LqBnGaebwnQQaDkodV |
16 |
|
3M's response to the EPA's PFOA Review Panel draft report argues that their extensive mortality studies on PFOA manufacturing workers indicate no adverse health effects, challenging the Panel's claims of positive results and certain adverse health effects, including cancer.
|
2005 |
AR226-3630
|
jNnmbQK0vxa580rQ1Nk1py1N9 |
3 |
|
The document is an analytical report from 3M Environmental Laboratory detailing the screening of 36 lots of commercial human serum for endogenous fluorochemicals, revealing that many target analytes, including PFOA and PFOS, were present at concentrations below the initial lower limits of quantitation of 100 - 300 ppt.
|
2005 |
AR226-3630
|
zVV3xjLKD1YLeOQLVEEgKoNm |
19 |
|
The document is a preliminary toxicity study report on perfluorooctanesulfonyl fluoride (POSF) conducted by 3M, detailing the effects of inhalation exposure in CD rats over one week.
|
2005 |
AR226-3630
|
2qVXVow6b4j5r74DeegY6Bam5 |
340 |
|
This document is a toxicity study report on perfluorooctanesulfonyl fluoride (POSF) conducted by 3M and Huntingdon Life Sciences, detailing the effects of inhalation exposure in CD rats over 13 weeks followed by a 4-week recovery period.
|
2005 |
AR226-3630
|
vBNYaND6xQExqN4K1daV6wDXb |
379 |
|
The document is an amended final report from 3M's Medical Department detailing a study on the metabolites of PFOS, specifically noting a change in the conclusion regarding FOSA as a metabolite of PFOS.
|
2004 |
AR226-3630
|
YD4M81M6J5pnk23dkq87r0EL8 |
4 |
|
A mortality study of perfluorooctanesulfonyl fluoride (POSF) manufacturing workers found a significant excess risk of bladder cancer associated with high levels of exposure to perfluorooctanesulfonate (PFOS), prompting further investigation through a questionnaire-based study to ascertain bladder cancer cases among the cohort.
|
2004 |
AR226-3630
|
LpQG98g6rEO4QKdwVyMdpwjq5 |
29 |
|
The document is a review of a toxicity study on perfluorooctanesulfonyl fluoride (POSF) conducted by 3M, indicating that while there are treatment-related effects observed in the liver, the urinary tract, including the kidneys and bladder, shows no significant abnormalities.
|
2004 |
AR226-3630
|
jm9DKGBpYaE3Qb9g6KEmqEEr2 |
2 |
|
The document is a final report from 3M's Corporate Toxicology department detailing an inter-species comparison study of the mechanisms of toxicity for perfluorooctanesulfonate (PFOS) and ammonium perfluorooctanoate (APFO) following intraperitoneal dosing in rats and guinea pigs, as well as oral dosing of N-ethyl perfluoroo
|
2004 |
AR226-3630
|
EvKK0KQ9JZEwJ1vnR8Yqxm5VL |
44 |
|
The document summarizes various toxicological studies conducted by 3M on perfluorinated compounds, specifically focusing on PFOS and N-EtFOSE, examining their mechanisms of toxicity in rats and guinea pigs through different dosing methods.
|
2004 |
AR226-3630
|
99p0xnjrj11NoB7r8EgaYVqN5 |
1 |
|
The document includes attachments related to 3M's fluorochemical submission, specifically detailing an analytical report on human serum for fluorochemicals and a final report on the effects of perfluorobutanesulfonate, perfluorohexanesulfonate, and perfluorooctanesulfonate on cholesterol metabolism.
|
2004 |
AR226-3630
|
3eXEaV180vqmmNd8p0LzLKbbn |
1 |
|
The document is a submission by 3M detailing a study by Butenhoff et al. on the characterization of risk for general population exposure to perfluorooctanoate (PFOA), published in Regulatory Toxicology and Pharmacology in April 2004.
|
2004 |
AR226-3630
|
B8j0zqnd1qmJ2YRQ9LMEnak2E |
1 |
|
The document discusses a study by Bruce H. Alexander from the University of Minnesota on bladder cancer in workers manufacturing perfluorooctanesulfonyl fluoride (POSF), submitted by 3M in November 2004.
|
2004 |
AR226-3630
|
mqJvd7Q3LL7jDKr72794YJoXZ |
1 |
|
The document is a submission by 3M detailing a study by Butenhoff et al. on the characterization of risk for general population exposure to perfluorooctanoate (PFOA), published in Regulatory Toxicology and Pharmacology in April 2004.
|
2004 |
AR226-3630
|
O3Q36R9QGYdjpw724GDyK5RxM |
1 |
|
The document is a submission from 3M regarding a study by DuPont on the effects of age on plasma concentrations of PFOA in post-weaning rats following oral gavage.
|
2004 |
AR226-3630
|
RaZyMXZap4KbnQ9RebpBOob1z |
1 |
|
This document is an amendment to a final report by 3M regarding a molecular biology study on the comparative effects of various perfluorinated compounds, including PFOS, N-EtFOSE, N-EtFOSA, FOSAA, and FOSA, on rats and guinea pigs following oral dosing.
|
2004 |
AR226-3630
|
kDVBgO1kR63EGm9Vkzwwxnvx0 |
1 |
|
This document includes a review letter by Samuel M. Cohen regarding a 90-day inhalation toxicity study on PFOS, dated June 18, 2004, and a peer review of a two-year oral toxicity-oncogenicity study in rats conducted by Experimental Pathology Laboratories and DuPont, dated June 25, 2004.
|
2004 |
AR226-3630
|
ypev5BjRmrpYzwavJ4n5j606r |
1 |
|
The document details two studies conducted by 3M's Medical Department on the toxicity mechanisms of perfluorooctanesulfonate (PFOS) and other perfluorinated compounds in rats and guinea pigs, focusing on inter-species comparisons and molecular biology findings.
|
2004 |
AR226-3630
|
Y97dV4yvzrJyym9qDwo3y1yO |
1 |
|
Empty document.
|
2004 |
AR226-3630
|
Ozwb36bpoB2YbN3bnV77NOEEM |
1 |
|
The document outlines various toxicological studies conducted by 3M on perfluorinated compounds, specifically focusing on PFOS and N-EtFOSE, including inter-species comparisons and cell proliferation studies in rats and guinea pigs.
|
2004 |
AR226-3630
|
O1QRdyKQD6e97r0RML9jdEQxj |
1 |
|
The document outlines a two-year oral toxicity and oncogenicity study of PFOA conducted on rats by DuPont, detailing the methodology and findings related to the compound's effects.
|
2004 |
AR226-3630
|
nk1jgJb99ZrVGZOV6kBRavrg1 |
15 |
|
The document characterizes the risk of general population exposure to perfluorooctanoate (PFOA), reporting that serum concentrations in the U.S. population are significantly lower than levels associated with adverse effects in toxicological studies, resulting in margins of exposure (MOE) ranging from 1600 to 8900.
|
2004 |
AR226-3630
|
reRvjmydRk9QzRyjjErdXDKmV |
18 |
|
The document details a study conducted by E.I. du Pont de Nemours and Company on the effects of age on plasma concentrations of ammonium perfluorooctanoate (PFOA) in post-weaning rats following oral gavage, completed on December 2, 2004, and compliant with Good Laboratory Practice standards.
|
2004 |
AR226-3630
|
d7Z8ZkvbdZGpRow8vOYd68J9 |
52 |
|
The document is a final report from 3M's Medical Department detailing a comparative molecular biology study on various perfluorinated compounds, including PFOS, conducted on rats and guinea pigs following oral dosing, with the study directed by Andrew M. Seacat.
|
2004 |
AR226-3630
|
b5z6mQzJzX1dL6J7ZyYB19Ybg |
209 |
|
The document is a report from DuPont detailing the findings of chronic feeding studies in rats regarding proliferative lesions of the exocrine pancreas associated with ammonium perfluorooctanoate (PFOA).
|
2003 |
AR226-3630
|
KRO4LgdazMKnXVn58GEK8v3ao |
8 |
|
The document is a review of proliferative lesions in the exocrine pancreas of rats from two chronic studies involving ammonium perfluorooctanoate (PFOA) conducted by S.R. Frame and E.E. McConnell.
|
2003 |
AR226-3630
|
2Nq6rZ1Ve45J9QxzOd5Z5jjV6 |
1 |
|
Empty document.
|
2003 |
AR226-3630
|
5bJBrJYaGxjqLMrEY38knweXV |
1 |
|
The document reviews pancreatic lesions from the DuPont APFO study, confirming the carcinogenic effects of APFO while noting discrepancies in hyperplasia diagnoses compared to a previous 3M study, ultimately concluding that the findings of the DuPont study remain valid.
|
2001 |
AR226-3630
|
wDdQYbQVBDGoYOKBMyZV1zydd |
5 |
|
The document evaluates the validation reports for the bioanalytical method of detecting PFOS and related analytes in human serum or plasma, sponsored by 3M Environmental Laboratories, focusing on various aspects of method accuracy and stability.
|
2001 |
AR226-3630
|
LJb30d3JZ9v4EZD15Vvy2EnOd |
26 |
|
The document discusses a slide review of pancreas lesions related to the DuPont study on APFO (perfluorooctanoic acid), conducted by E.E. McConnell and J.R. Foster in November 2001.
|
2001 |
AR226-3630
|
3QqR4OpJbbDa7RDQBmKGrYxza |
1 |
|
The document discusses the evaluation of method validation reports for PFOS and related analytes in human serum or plasma, submitted by 3M for compliance with FDA requirements.
|
2001 |
AR226-3630
|
4QQ2Kd9Lq50MQKVxwg3dxq61x |
1 |
|
Empty document.
|
2001 |
AR226-3630
|
rxjd8z5n54vBJdoDZwo7OJvkJ |
1 |
|
The document is an amended final report of a cell proliferation study conducted by 3M on N-Ethyl Perfluorooctanesulfonamido Ethanol (N-EtFOSE), Perfluorooctane Sulfonic Acid Potassium Salt (PFOS), and N-Ethyl Perfluorooctanesulfonamide (N-EtFOSA) in
|
2000 |
AR226-3630
|
yk76Vw09LDq03ez5rLymB3Jp2 |
74 |
|
The document is a final report from TherImmune Research Corporation detailing a cell proliferation study involving N-Ethyl Perfluorooctanesulfonamido Ethanol (N-EtFOSE), Perfluorooctane Sulfonic Acid Potassium Salt (PFOS), and N-Ethyl Perfluorooctanesulfonamide (PFOSA) in rats, sponsored
|
2000 |
AR226-3630
|
npGr6jRb7ORkQb2B6GawZOM32 |
62 |
|
The document is a pathology peer review report on a 26-week capsule toxicity study of Ammonium Perfluorooctanoate (APFO) conducted in Cynomolgus monkeys by Covance, dated February 3, 2000.
|
2000 |
AR226-3630
|
zQ72ra8o0E9KYOb5Q4gYd2wMg |
1 |
|
The document outlines various studies and comments related to PFOA (perfluorooctanoate) conducted by 3M and other researchers between May 2000 and October 2005, focusing on toxicology, epidemiology, and medical surveillance.
|
2000 |
AR226-3630
|
rek4Vd24vR9yr37z3V5LwQ8jV |
2 |
|
The document is a final report of a cell proliferation study conducted by Charles River Laboratories on N-Ethyl Perfluorooctanesulfonamido Ethanol (N-EtFOSE), Perfluorooctane Sulfonic Acid Potassium Salt (PFOS), and N-Ethyl Perfluorooctansulfonamide (N-EtFOSA) in rats
|
2000 |
AR226-3630
|
jmEJzMyarYKGModNmGdLRQQp2 |
1 |
|
The document is a cell proliferation study conducted by TherImmune Research Corporation on N-Ethyl Perfluorooctanesulfonamide (N-EtFOSE), Perfluorooctane Sulfonic Acid Potassium Salt (PFOS), and N-Ethyl Perfluorooctansulfonamide (PFOSA) in rats, submitted by 3M in May
|
2000 |
AR226-3630
|
reerLeppmjQG70LMQwRVB8rXv |
1 |
|
Empty document.
|
2000 |
AR226-3630
|
Rpew3zkRJz35J5GYOa5k0wnyX |
1 |
|
The document discusses the findings of a two-year toxicity and carcinogenicity study of fluorochemical FC-143 conducted by 3M Company, highlighting liver toxicity and neoplasms in rats, with specific attention to hepatic lesions and enzyme elevations in male rats.
|
1987 |
AR226-3630
|
Vv0wN8m9ej3Za9QkdbZq8dxK |
6 |
|
This document appears to be related to a submission on fluorochemicals, specifically discussing toxicology, epidemiology, and medical surveillance concerning PFOA and PFOS, along with comments from a Science Advisory Board.
|
1987 |
AR226-3630
|
RJM7gdGXD407mQw0Qek26g5VE |
1 |
|
Empty document.
|
1987 |
AR226-3630
|
b5M14ZRegZjBRjEymOJN9vmj6 |
1 |
|
The document is an attachment to a letter from 3M detailing various studies related to the toxicity and carcinogenicity of perfluorooctanoic acid (PFOA), including findings from studies conducted on rats and monkeys.
|
1987 |
AR226-3630
|
g3LaJbNaOXp4Y328v5Z2nbDV |
1 |
|
Empty document.
|
1987 |
AR226-3630
|
2RJLXnxRXZby8KrDO3mYxNqQ6 |
1 |
|
The document summarizes various studies and reports related to the toxicity and carcinogenicity of PFOA (perfluorooctanoate) conducted by 3M and DuPont from 1987 to 2005, including findings from toxicity studies in rats and monkeys.
|
1987 |
AR226-3630
|
M4xqMwG8r86xvKK0xpVNrmzZV |
1 |
|
The document summarizes various toxicology studies and findings related to Perfluorooctanesulfonyl fluoride (POSF), including a 5-day and a 90-day inhalation toxicity study conducted by Huntingdon Life Sciences Ltd., as well as a review letter and a study on bladder cancer in manufacturing workers exposed to POSF.
|
1987 |
AR226-3630
|
ZJ2aOaNYZ7z8GwMrmEXjJVeNY |
1 |
|
Empty document.
|
1987 |
AR226-3630
|
pB2jap19LB1kNJKLe1zy324wd |
1 |
|
The document is a review letter discussing a two-year toxicity and carcinogenicity study of PFOA (fluorochemical FC-143) in rats, authored by Greg Sykes from Haskell Laboratory for Toxicology and Industrial Medicine and addressed to Charles Reinhardt.
|
1987 |
AR226-3630
|
O1exVM1VgqRQRmDm05RvkvBDL |
1 |
|
Empty document.
|
1987 |
AR226-3630
|
3N3RxGKRogjQ8rg7yD4m6B893 |
1 |
|
The document reports on a study commissioned by 3M, conducted by TNO, examining the effects of perfluorobutanesulfonate, perfluorohexanesulfonate, and perfluorooctanesulfonate on cholesterol metabolism in vitro, with findings related to cholesterol and bile acid synthesis in primary rat hepatocytes.
|
— |
AR226-3630
|
doLyErdQKv5BkNvZqZkY4G2e |
35 |
|
This is a notice from 3M regarding the submission of documents to the EPA related to fluorochemistry, emphasizing that the documents are for read-only purposes and that original paper copies will be maintained for accuracy.
|
— |
AR226-3630
|
x1YMVQ6wwaq6xZ1rRbZax0Q46 |
1 |
|
The document is a pathology peer review report confirming the original conclusions of a 26-week toxicity study with ammonium perfluorooctanoate (APFO) in cynomolgus monkeys, indicating that the cause of moribundity in one animal was determined while the cause in another was unclear, but unlikely related to APFO treatment.
|
— |
AR226-3630
|
vVmNRmbdO47yEjQyJZj2mJ4mZ |
1 |
|
The document reports on a 13-week inhalation toxicity study of Perfluorooctanesulfonyl fluoride (POSF) in CD rats, followed by a 4-week recovery period, conducted by HWAHCPEENaluuocm2nnGoo8ttbnliiLlnnrb4eAigguHydddNrgSRyooeD.
|
— |
AR226-3630
|
pBEow2aqexBbJV66nZRNqnZ1j |
377 |